Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.59M | 4.72M | 8.14M | 8.12M | 3.56M |
| Total Depreciation and Amortization | 198.00K | 203.60K | 167.90K | 167.60K | 187.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -498.80K | -512.90K | -2.67M | -2.66M | 4.84M |
| Change in Net Operating Assets | -- | -- | -2.12M | -2.12M | -- |
| Cash from Operations | 4.29M | 4.41M | 3.52M | 3.51M | 8.60M |
| Capital Expenditure | -18.90K | -19.40K | -90.50K | -90.30K | -1.73M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.76M | -10.03M | -4.20M | -4.19M | -3.49M |
| Cash from Investing | -9.77M | -10.05M | -4.29M | -4.28M | -5.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -93.50K | -93.50K | -91.50K | -91.50K | -82.10K |
| Issuance of Common Stock | -- | -- | 2.08M | 2.08M | -- |
| Repurchase of Common Stock | -126.00K | -126.00K | -2.45M | -2.45M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -815.70K | -838.70K | 0.00 | 0.00 | -804.90K |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -958.60K | -985.70K | -308.80K | -308.20K | -858.50K |
| Foreign Exchange rate Adjustments | 459.60K | 472.60K | -109.50K | -109.30K | -263.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.99M | -6.16M | -1.19M | -1.19M | 2.26M |